Kollmar, Otto

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.lastpage","176"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.editor","Oellerich, Michael"],["dc.contributor.editor","Dasgupta, Amitava"],["dc.date.accessioned","2020-05-22T06:58:17Z"],["dc.date.available","2020-05-22T06:58:17Z"],["dc.date.issued","2016"],["dc.description.abstract","Genome transplant dynamics is a particularly promising new approach for the detection of graft injury based on the determination of graft-derived circulating cell-free DNA (cfDNA) in the blood of the recipient. An increase of donor DNA is an early indication of organ damage. A novel potential routine assay for graft-derived circulating cfDNA quantification has been developed using droplet digital polymerase chain reaction for the determination of the donor/recipient circulating cfDNA ratio. This method is very cost-effective and provides results on the same day. Monitoring graft-derived cfDNA has the advantage that it directly interrogates the health of the donor organ, and it allows early detection of transplant injury (“liquid biopsy”). The detection of subclinical rejection would be desirable to allow early intervention. Undiagnosed chronic damage can result in chronic rejection. The determination of graft-derived circulating cfDNA may complement or possibly replace other approaches for post-transplant monitoring, and it may improve the chances of long-term graft survival. This method will be helpful to individualize immunosuppressive regimens. Personalized immunosuppression will in the future shift emphasis from reaction to prevention, which could make immunosuppressive drugs safer and more effective and also reduce the cost of health care."],["dc.identifier.doi","10.1016/B978-0-12-800885-0.00007-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65676"],["dc.language.iso","en"],["dc.publisher","Elsevier"],["dc.publisher.place","San Diego"],["dc.relation.doi","10.1016/C2013-0-19247-1"],["dc.relation.isbn","978-0-12-800885-0"],["dc.relation.ispartof","Personalized Immunosuppression in Transplantation"],["dc.title","Graft-derived cell-free DNA as a marker of graft integrity after transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","373"],["dc.bibliographiccitation.lastpage","386"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Blum, Anna"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.editor","Preedy, V. R."],["dc.contributor.editor","Patel, V. B."],["dc.date.accessioned","2020-05-22T07:14:29Z"],["dc.date.available","2020-05-22T07:14:29Z"],["dc.date.issued","2017"],["dc.description.abstract","Improvement of long-term patient and graft outcome is still a challenge in liver transplantation. Personalized approaches to immunosuppressive treatment of liver transplant patients are currently under investigation, as conventional markers have limited usefulness to predict drug efficacy. The presence of graft-derived cell-free DNA (GcfDNA) in the plasma of liver transplant recipients opens up the possibility of monitoring allograft injury through measurement of this molecular marker. A rapid, cost-effective droplet digital PCR (ddPCR) method has been developed for the quantification of donor DNA. GcfDNA has shown to be useful for the detection of subclinical and full-blown acute rejection and non-rejection-related liver injury (e.g., HCV infection, liver trauma, ischemia/reperfusion damage). GcfDNA allows for the early detection of transplant injury (“liquid biopsy”) and enables earlier more effective treatment intervention. It is especially helpful to guide changes in immunosuppression and to monitor immunosuppression minimization. This new approach may contribute to achieve more effective, less toxic personalized immunosuppression."],["dc.identifier.doi","10.1007/978-94-007-7675-3_10"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65684"],["dc.language.iso","en"],["dc.publisher","Springer"],["dc.publisher.place","Dordrecht"],["dc.relation.eisbn","978-94-007-7675-3"],["dc.relation.isbn","978-94-007-7674-6"],["dc.relation.ispartof","Biomarkers in Liver Disease"],["dc.title","Graft-derived cell-free DNA as a biomarker in liver transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S241"],["dc.bibliographiccitation.journal","Liver Transplantation"],["dc.bibliographiccitation.lastpage","S242"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schuetz, Ekkehardt"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:39:07Z"],["dc.date.available","2018-11-07T09:39:07Z"],["dc.date.issued","2014"],["dc.identifier.isi","000339959602142"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33206"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Joint International Congress of ILTS, ELITA and LICAGE"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1527-6473"],["dc.relation.issn","1527-6465"],["dc.title","Graft Derived Cell-Free DNA as an Early Organ Integrity Biomarker after Liver Transplantation of a HELLP Syndrome Donor Liver."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S75"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.lastpage","S79"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Schütz, Ekkehard"],["dc.date.accessioned","2020-12-10T18:19:52Z"],["dc.date.available","2020-12-10T18:19:52Z"],["dc.date.issued","2016"],["dc.description.abstract","Although short-term success after solid organ transplantation is good, long-term graft and recipient survival are both not satisfactory. Despite therapeutic drug monitoring (TDM) of immunosuppressive drugs (ISDs), both excessive and insufficient immunosuppression still do occur. There is a need for new biomarkers that, when combined with TDM, can be used to provide more effective and less toxic, personalized immunosuppression to improve long-term survival. Currently used methods are insufficient to rapidly, cost-effectively, and directly interrogate graft integrity after solid organ transplantation. However, because organ transplants are also genome transplants, measurement of graft-derived circulating cell-free DNA (GcfDNA) has shown promise as a way to improve both graft and recipient outcomes after solid organ transplantation through the early detection of severe graft injury, enabling an early intervention. A newly developed droplet digital polymerase chain reaction (ddPCR) method has advantages over expensive high-throughput sequencing methods to rapidly quantify GcfDNA percentages and absolute amounts. This procedure does not require donor DNA and therefore can be applied to any organ donor/recipient pair. The droplet digital polymerase chain reaction method allows for the early, sensitive, specific, and cost-effective direct assessment of graft integrity and can be used to define individual responses to ISDs including the minimal ISD exposures necessary to prevent rejection. This is especially important in patients undergoing ISD switches due to ISD toxicity, infections, or malignancies. Although prospective, multicenter clinical trials in liver, heart, and kidney transplantation have not been completed, early results suggest that GcfDNA can be combined with TDM to guide changes in immunosuppression to provide more effective, and less toxic treatment. Personalized immunosuppression will shift emphasis in transplantation from reaction to prevention and could improve outcome at lower health care costs."],["dc.identifier.doi","10.1097/FTD.0000000000000239"],["dc.identifier.isi","000377003400009"],["dc.identifier.issn","0163-4356"],["dc.identifier.pmid","26418703"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75409"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1536-3694"],["dc.relation.issn","0163-4356"],["dc.title","Graft-Derived Cell-Free DNA as a Marker of Transplant Graft Injury"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1732"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Clinical Chemistry"],["dc.bibliographiccitation.lastpage","1741"],["dc.bibliographiccitation.volume","59"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Bierau, Sarah"],["dc.contributor.author","Balzer, Stefan"],["dc.contributor.author","Andag, Reiner"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Mörer, Onnen"],["dc.contributor.author","Slotta, Jan E."],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.date.accessioned","2020-05-22T07:07:40Z"],["dc.date.available","2020-05-22T07:07:40Z"],["dc.date.issued","2013"],["dc.description.abstract","BACKGROUND Cell-free DNA (cfDNA) from grafts in the circulation of transplant recipients is a potential biomarker of rejection. Its usefulness was investigated after heart transplantation during the maintenance phase by use of microarrays and massive parallel sequencing of donor and recipient DNA. Disadvantages of these methods are high costs, long turnaround times, and need for donor DNA. Therefore, we sought to develop a rapid and cost-effective method using digital droplet PCR (ddPCR). METHODS Plasma samples were collected from stable recipients after liver (LTx, n = 10), kidney (KTx, n = 9), and heart (HTx, n = 8) transplantation as well as from 7 additional patients directly after LTx. Known single-nucleotide polymorphisms were selected for high minor allelic frequencies, of which 41 hydrolysis probe assays were established. Plasma cfDNA was preamplified, followed by conventional real-time PCR to define informative (heterologous) SNPs, which were then used for quantification (percentage) of graft-derived cfDNA (GcfDNA) using ddPCR. RESULTS Mean recovery was 94% (SD, 13%) with an imprecision of 4%–14% with the use of controls with 2% minor allele. GcfDNA in stable patients was <6.8% (LTx), <2.5% (KTx), and <3.4% (HTx). On the day of LTx, GcfDNA was approximately 90% and by day 10 it was <15% in complication-free LTx recipients. In 2 patients with biopsy-proven rejection, GcfDNA increased to >60%, whereas in 1 patient with cholestasis no increase was found. CONCLUSIONS A novel, cost-effective, rapid technique was developed to quantify GcfDNA in transplant recipients. This technique embodies a promising, potentially universal biomarker for early detection of rejection, which could enable more effective therapeutic interventions."],["dc.identifier.doi","10.1373/clinchem.2013.210328"],["dc.identifier.pmid","24061615"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65680"],["dc.language.iso","en"],["dc.relation.eissn","1530-8561"],["dc.relation.issn","0009-9147"],["dc.title","Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S107"],["dc.bibliographiccitation.journal","Liver Transplantation"],["dc.bibliographiccitation.lastpage","S108"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Slotta, Jan Erik"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Birau, Sarah"],["dc.contributor.author","Balzer, Stefan"],["dc.contributor.author","Andag, Reiner"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Moerer, Onnen"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schuetz, Eckehardt"],["dc.contributor.author","Kollmar, Otto"],["dc.date.accessioned","2018-11-07T09:39:07Z"],["dc.date.available","2018-11-07T09:39:07Z"],["dc.date.issued","2014"],["dc.identifier.isi","000339959601015"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33207"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Joint International Congress of ILTS, ELITA and LICAGE"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1527-6473"],["dc.relation.issn","1527-6465"],["dc.title","Quantification of Donor DNA in the Circulation after Liver Transplantation As a Potential Universal Rejection Biomarker Using Digital Droplet PCR."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e43"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Transplantation Journal"],["dc.bibliographiccitation.lastpage","e45"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Slotta, Jan Erik"],["dc.date.accessioned","2018-11-07T09:35:15Z"],["dc.date.accessioned","2020-05-22T07:54:43Z"],["dc.date.available","2018-11-07T09:35:15Z"],["dc.date.available","2020-05-22T07:54:43Z"],["dc.date.issued","2014"],["dc.identifier.isi","000341854800007"],["dc.identifier.pmid","25171533"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65700"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.eissn","1534-6080"],["dc.relation.issn","0041-1337"],["dc.title","Graft-Derived Cell-Free DNA as an Early Organ Integrity Biomarker After Transplantation of a Marginal HELLP Syndrome Donor Liver"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e1002286"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","PLoS Medicine"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Fischer, Anna"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Harden, Markus"],["dc.contributor.author","Koch, Martina"],["dc.contributor.author","Wuensch, Tilo"],["dc.contributor.author","Stockmann, Martin"],["dc.contributor.author","Nashan, Bjoern"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Matthaei, Johannes"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Oellerich, Michael"],["dc.date.accessioned","2018-11-07T10:25:24Z"],["dc.date.accessioned","2020-05-22T07:30:58Z"],["dc.date.available","2018-11-07T10:25:24Z"],["dc.date.available","2020-05-22T07:30:58Z"],["dc.date.issued","2017"],["dc.description.abstract","Background Graft-derived cell-free DNA (GcfDNA), which is released into the blood stream by necrotic and apoptotic cells, is a promising noninvasive organ integrity biomarker. In liver transplantation (LTx), neither conventional liver function tests (LTFs) nor immunosuppressive drug monitoring are very effective for rejection monitoring. We therefore hypothesized that the quantitative measurement of donor-derived cell-free DNA (cfDNA) would have independent value for the assessment of graft integrity, including damage from acute rejection. Methods and findings Traditional LFTs were performed and plasma GcfDNA was monitored in 115 adults post-LTx at three German transplant centers as part of a prospective, observational, multicenter cohort trial. GcfDNA percentage (graft cfDNA/total cfDNA) was measured using droplet digital PCR (ddPCR), based on a limited number of predefined single nucleotide polymorphisms, enabling same-day turn-around. The same method was used to quantify blood microchimerism. GcfDNA was increased >50% on day 1 post-LTx, presumably from ischemia/reperfusion damage, but rapidly declined in patients without graft injury within 7 to 10 d to a median <10%, where it remained for the 1-y observation period. Of 115 patients, 107 provided samples that met preestablished criteria. In 31 samples taken from 17 patients during biopsy-proven acute rejection episodes, the percentage of GcfDNA was elevated substantially (median 29.6%, 95% CI 23.6%-41.0%) compared with that in 282 samples from 88 patients during stable periods (median 3.3%, 95% CI 2.9%-3.7%; p < 0.001). Only slightly higher values (median 5.9%, 95% CI 4.4%-10.3%) were found in 68 samples from 17 hepatitis C virus (HCV)-positive, rejection-free patients. LFTs had low overall correlations (r = 0.28-0.62) with GcfDNA and showed greater overlap between patient subgroups, especially between acute rejection and HCV+ patients. Multivariable logistic regression modeling demonstrated that GcfDNA provided additional LFT-independent information on graft integrity. Diagnostic sensitivity and specificity were 90.3% (95% CI 74.2%-98.0%) and 92.9% (95% CI 89.3%-95.6%), respectively, for GcfDNA at a threshold value of 10%. The area under the receiver operator characteristic curve was higher for GcfDNA (97.1%, 95% CI 93.4%-100%) than for same-day conventional LFTs (AST: 95.7%; ALT: 95.2%; gamma-GT: 94.5%; bilirubin: 82.6%). An evaluation of microchimerism revealed that the maximum donor DNA in circulating white blood cells was only 0.068%. GcfDNA percentage can be influenced by major changes in host cfDNA (e.g., due to leukopenia or leukocytosis). One limitation of our study is that exact time-matched GcfDNA and LFT samples were not available for all patient visits. Conclusions In this study, determination of GcfDNA in plasma by ddPCR allowed for earlier and more sensitive discrimination of acute rejection in LTx patients as compared with conventional LFTs. Potential blood microchimerism was quantitatively low and had no significant influence on GcfDNA value. Further research, which should ideally include protocol biopsies, will be needed to establish the practical value of GcfDNA measurements in the management of LTx patients."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2017"],["dc.identifier.doi","10.1371/journal.pmed.1002286"],["dc.identifier.isi","000400768500015"],["dc.identifier.pmid","28441386"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14418"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42852"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65693"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1549-1676"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","136"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.lastpage","140"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Streit, Frank"],["dc.contributor.author","Walson, Philip D."],["dc.date.accessioned","2018-11-07T09:41:38Z"],["dc.date.accessioned","2020-05-22T07:08:44Z"],["dc.date.available","2018-11-07T09:41:38Z"],["dc.date.available","2020-05-22T07:08:44Z"],["dc.date.issued","2014"],["dc.description.abstract","Background:Immunosuppressant therapeutic ranges for transplant patients have traditionally been established by indirect clinical means. However, liquid biopsy methods measuring graft-derived cell-free DNA (GcfDNA) in blood directly interrogate donor organ integrity. This study was performed to determine whether GcfDNA quantification could be used to reexamine minimally effective trough tacrolimus (Tacro) concentrations in liver transplantation (LTx) patients.Methods:As part of a large prospective study to demonstrate the ability of GcfDNA to identify early graft rejection, 10 adult white LTx patients [8 men, 2 women, 3 hepatitis C virus (HCV) positive; mean SD age (years) = 56 9.4] had simultaneous GcfDNA and whole-blood trough Tacro concentrations measured between days 5 and 30 after LTx. Samples were analyzed using droplet digital polymerase chain reaction for GcfDNA and liquid chromatography tandem mass spectrometry for Tacro. GcfDNA and trough Tacro concentrations were then compared to identify Tacro concentrations associated with intact graft integrity.Results:Although there were large individual differences, there was a highly significant (Fisher P = 0.00002) segregation between whole-blood Tacro concentrations of 8 g/L and normal (10%) GcfDNA percentages. The best discrimination in this population between effective and ineffective trough Tacro concentrations was estimated to be at 6.8 g/L (P < 10(-7)). Compared with HCV- patients (n = 7), the 3 HCV+ patients had more variable associations between GcfDNA percentages and Tacro concentrations.Conclusions:Direct measurement of graft integrity using GcfDNA was useful to confirm the lower limit of the therapeutic ranges for trough Tacro concentrations after LTx. It would probably be useful to do so also for other immunosuppressant drugs and after other solid organ transplants. The method might be especially useful to detect graft injury during immunosuppressant dose minimization strategies."],["dc.description.sponsorship","German Federal Ministry of Education and Research [FKZ: 01ES1102]"],["dc.identifier.doi","10.1097/FTD.0000000000000044"],["dc.identifier.isi","000333200900002"],["dc.identifier.pmid","24452066"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65681"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.eissn","1536-3694"],["dc.relation.issn","0163-4356"],["dc.title","Use of Graft-Derived Cell-Free DNA as an Organ Integrity Biomarker to Reexamine Effective Tacrolimus Trough Concentrations After Liver Transplantation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]